clock.bio, a Cambridge, UK-based healthspan biotech company, raised $5.3M in Seed funding.
The round was led by LocalGlobe, with participation from BlueYard Capital, Onsight Ventures, and Dr. Jonathan Milner, the Founder of Abcam.
The company intends to use the funds to generate its Atlas of Rejuvenation Factors and do the next steps in validation and target prioritization.
Led by CEO Markus Gstƶttner, CTO Rodrigo Santos, and Chairman and co-founder Mark Kotter, clock.bio aims to increase human healthspan by developing novel treatments that can prevent and treat age-related diseases by decoding the rejuvenation programs present in human cells. The company is structured as a partnership of scientists and operators bound together by a shared ethical outlook.
Located at the Milner Therapeutics Institute at the University of Cambridge, clock.bio has set out to decode this rejuvenation mechanism, understand which genes regulate this process, and translate the resulting insights to clinical applications. Running a genome-wide CRISPR screen, with single-cell RNA-sequencing of over 3 million cells that generated 20 terabytes of data, clock.bio was able to decode the ārejuvenation mechanismā innate in human stem cells, identifying more than 100 genes that jointly constitute an “Atlas of Rejuvenation Factors.”
FinSMEs
09/10/2024